Tagris­so reach­es OS end­point in PhI­II EGFR-mu­tat­ed lung can­cer tri­al

As­traZeneca put out word Thurs­day morn­ing that its lung can­cer ther­a­py and EGFR in­hibitor Tagris­so met a sec­ondary end­point of over­all sur­vival in a Phase III tri­al.

Ac­cord­ing to the phar­ma gi­ant, Tagris­so met the end­point in the place­bo-con­trolled ADAU­RA tri­al, which has been test­ing the drug in the ad­ju­vant set­ting in pa­tients with ear­ly-stage, EGFR-mu­tat­ed non-small cell lung can­cer af­ter a tu­mor was al­ready re­moved through surgery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER